Browsing Tag
CAR T cell therapy
8 posts
Fate Therapeutics unveils ACR 2025 results: FT819 off-the-shelf CAR T drives immune remodeling in lupus
Discover how Fate Therapeutics’ FT819 off-the-shelf CAR T therapy is reshaping lupus treatment through durable immune remodeling and long-term remission.
Bristol Myers Squibb’s CD19 NEX-T therapy shows 94% off immunosuppressants in early Phase 1 results
Bristol Myers Squibb’s CAR T cell therapy shows early promise in autoimmune disorders. Find out what the data means for the stock and the wider market.
Innovent Biologics, IASO Bio strengthen collaboration with equity investment and licensing deal
Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell…
FDA grants accelerated approval to Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Bristol Myers Squibb (NYSE: BMY) has announced a significant breakthrough in the treatment of follicular lymphoma with the…
Bristol Myers Squibb and 2seventy bio’s Abecma gets positive FDA committee vote for multiple myeloma
In a significant development in the healthcare industry, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq:…
AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash…
Verily, Kyverna Therapeutics forge collaboration for autoimmune research
Verily, an Alphabet precision health technology company, and Kyverna Therapeutics, a clinical-stage cell therapy company, have announced a…
Bristol Myers Squibb gets FDA priority review for Breyanzi sBLA
Bristol Myers Squibb (BMS) has secured priority review from the US Food and Drug Administration (FDA) for its…